# A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

> **NCT04505683** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sihuan Pharmaceutical Holdings Group Ltd.** · enrollment: 112 (actual)

## Conditions studied

- Complicated Urinary Tract Infection Including Acute Pyelonephritis

## Interventions

- **DRUG:** Benapenem
- **DRUG:** Ertapenem

## Key facts

- **NCT ID:** NCT04505683
- **Lead sponsor:** Sihuan Pharmaceutical Holdings Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2020-05-08
- **Final completion:** 2020-05-08
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04505683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04505683, "A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04505683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*